Disc Medicine, Inc. Common Stock IRON
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:49:49.937Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:32.739221105Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:49:49.308525+00:00
Disc Medicine, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 80.86 | 53.9% | 7.5% | |||
| 25Δ | 94.66 | 77.1% | 11.2% | 81.86 | 55.5% | 6.8% |
| 30Δ | 92.62 | 71.0% | 9.1% | 82.85 | 57.2% | 6.1% |
| 35Δ | 90.58 | 64.9% | 7.1% | 83.85 | 58.8% | 5.4% |
| 40Δ | 89.18 | 65.7% | 6.1% | 84.85 | 60.4% | 4.7% |
| 45Δ | 88.03 | 69.1% | 5.5% | 85.73 | 58.4% | 4.1% |
| 50Δ | 86.88 | 72.6% | 5.0% | 86.59 | 55.7% | 3.5% |
| 55Δ | 85.73 | 76.0% | 4.5% | 87.45 | 53.0% | 2.9% |
| 60Δ | 84.54 | 77.4% | 3.9% | 88.30 | 50.3% | 2.4% |
| 65Δ | 83.29 | 75.0% | 3.2% | 89.16 | 47.7% | 1.8% |
| 70Δ | 82.05 | 72.7% | 2.6% | 90.03 | 45.1% | 1.2% |
| 75Δ | 80.80 | 70.4% | 1.9% | 91.27 | 45.1% | 1.0% |
| 80Δ | 79.48 | 67.4% | 1.4% | 92.51 | 45.1% | 0.7% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 80.86
- IV
- 53.9%
- B/E move
- 7.5%
25Δ
- Pseudo strike
- 94.66
- IV
- 77.1%
- B/E move
- 11.2%
- Pseudo strike
- 81.86
- IV
- 55.5%
- B/E move
- 6.8%
30Δ
- Pseudo strike
- 92.62
- IV
- 71.0%
- B/E move
- 9.1%
- Pseudo strike
- 82.85
- IV
- 57.2%
- B/E move
- 6.1%
35Δ
- Pseudo strike
- 90.58
- IV
- 64.9%
- B/E move
- 7.1%
- Pseudo strike
- 83.85
- IV
- 58.8%
- B/E move
- 5.4%
40Δ
- Pseudo strike
- 89.18
- IV
- 65.7%
- B/E move
- 6.1%
- Pseudo strike
- 84.85
- IV
- 60.4%
- B/E move
- 4.7%
45Δ
- Pseudo strike
- 88.03
- IV
- 69.1%
- B/E move
- 5.5%
- Pseudo strike
- 85.73
- IV
- 58.4%
- B/E move
- 4.1%
50Δ
- Pseudo strike
- 86.88
- IV
- 72.6%
- B/E move
- 5.0%
- Pseudo strike
- 86.59
- IV
- 55.7%
- B/E move
- 3.5%
55Δ
- Pseudo strike
- 85.73
- IV
- 76.0%
- B/E move
- 4.5%
- Pseudo strike
- 87.45
- IV
- 53.0%
- B/E move
- 2.9%
60Δ
- Pseudo strike
- 84.54
- IV
- 77.4%
- B/E move
- 3.9%
- Pseudo strike
- 88.30
- IV
- 50.3%
- B/E move
- 2.4%
65Δ
- Pseudo strike
- 83.29
- IV
- 75.0%
- B/E move
- 3.2%
- Pseudo strike
- 89.16
- IV
- 47.7%
- B/E move
- 1.8%
70Δ
- Pseudo strike
- 82.05
- IV
- 72.7%
- B/E move
- 2.6%
- Pseudo strike
- 90.03
- IV
- 45.1%
- B/E move
- 1.2%
75Δ
- Pseudo strike
- 80.80
- IV
- 70.4%
- B/E move
- 1.9%
- Pseudo strike
- 91.27
- IV
- 45.1%
- B/E move
- 1.0%
80Δ
- Pseudo strike
- 79.48
- IV
- 67.4%
- B/E move
- 1.4%
- Pseudo strike
- 92.51
- IV
- 45.1%
- B/E move
- 0.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 60.51% | |
| 60.99% | |
| 60.85% | |
| 62.73% | |
| 96.27% | |
| 70.56% | |
| 70.62% | |
| 66.66% | |
| 68.22% | |
| 69.34% | |
| 69.51% | |
| 68.83% | |
| 73.29% | |
| 72.20% | |
| 72.01% | |
| 74.81% | |
| 77.25% | |
| 78.31% | |
| 75.08% | |
| 71.60% | |
| 79.81% | |
| 88.22% | |
| 87.16% | |
| 94.87% | |
| 82.25% | |
| 86.02% | |
| 87.78% | |
| 88.50% | |
| 89.54% | |
| 93.61% | |
| 99.49% | |
| 103.22% | |
| 113.64% | |
| 116.31% | |
| 118.71% | |
| 123.52% | |
| 130.93% | |
| 138.77% | |
| 147.42% | |
| 155.12% | |
| 175.89% | |
| 168.53% | |
| 167.44% | |
| 178.52% | |
| 151.67% | |
| 49.75% | |
| 47.12% | |
| 46.32% | |
| 47.72% | |
| 44.14% | |
| 45.00% | |
| 47.32% | |
| 45.88% | |
| 47.37% | |
| 49.27% |
Biotechnology
IVA
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH),…
More →IVVD
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious…
More →JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer…
More →JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and…
More →JBIO
Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company is…
More →JSPR
Jasper Therapeutics Inc (JSPR) is a pioneering biopharmaceutical company dedicated to advancing hematopoietic stem cell therapies aimed at improving treatment outcomes for…
More →